Literature DB >> 1316969

Alanine series of ovine corticotropin releasing factor (oCRF): a structure-activity relationship study.

W D Kornreich1, R Galyean, J F Hernandez, A G Craig, C J Donaldson, G Yamamoto, C Rivier, W Vale, J Rivier.   

Abstract

Previous structure-activity relationship studies of CRF have shown that residues 1-4 were not necessary for receptor binding or transduction, that residues 4-8 were important for activation, and that residues 12-41 were mostly responsible for binding. Finally it was proposed that CRF assumed an alpha-helical structure when interacting with its receptor. By systematic substitution of each residue (except residues 1-4) in ovine CRF (oCRF) by Ala, we have investigated the role played by individual side chains in receptor recognition and activation. Out of 33 analogues (synthesized using SPPS on an MBHA resin, purified by RPHPLC and characterized by amino acid and mass spectral analyses), a significant loss of biological potency (less than 1% potency of native) was observed for 6 analogues ([Ala6], [Ala8], [Ala10], [Ala12], [Ala14], and [Ala38]); 12 analogues had biological potencies ranging from 1% to 60% and ranked as follows: [Ala35] less than [Ala16] less than [Ala9] less than [Ala19] less than [Ala15] less than [Ala13] less than [Ala7] less than [Ala23] less than [Ala11] less than or equal to [Ala21] less than [Ala27] less than or equal to [Ala18]; 8 analogues were found to be equipotent (greater than 60% and less than 150%) ([Ala5], [Ala17], [Ala26], [Ala29], [Ala30], [Ala34], [Ala36], and [Ala37]; and 7 analogues were found to be approximately 2-5 times more potent than native oCRF ([Ala25] = [Ala40] less than or equal to [Ala39] less than or equal to [Ala33] less than [Ala20] less than [Ala22] less than [Ala32], in an in vitro pituitary cell culture assay. In summary, the Ala substitutions which showed the greatest loss of potency (less than 1% of native oCRF) were those replacing hydrophobic residues while those showing the greatest increase in potency were replacing hydrophilic residues. Of the 22 Ala-containing analogues in the C-terminal half of the molecule, 17 analogues have equal or greater potencies than native oCRF. Substitution of Ala in the N-terminal region (residues 5-19) on the other hand is generally detrimental to biological activity. These results suggest that the side chains of residues 5-19 are very important for receptor binding and activation while, in the C-terminal region, the amino acid side chains may be more responsible for structural conservation than for functional expression.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1316969     DOI: 10.1021/jm00088a024

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  14 in total

1.  Constitutive activation of tethered-peptide/corticotropin-releasing factor receptor chimeras.

Authors:  S M Nielsen; L Z Nielsen; S A Hjorth; M H Perrin; W W Vale
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

2.  Structure of the N-terminal domain of a type B1 G protein-coupled receptor in complex with a peptide ligand.

Authors:  Christy Rani R Grace; Marilyn H Perrin; Jozsef Gulyas; Michael R Digruccio; Jeffrey P Cantle; Jean E Rivier; Wylie W Vale; Roland Riek
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-12       Impact factor: 11.205

3.  Molecular recognition of corticotropin-releasing factor by its G-protein-coupled receptor CRFR1.

Authors:  Augen A Pioszak; Naomi R Parker; Kelly Suino-Powell; H Eric Xu
Journal:  J Biol Chem       Date:  2008-09-17       Impact factor: 5.157

Review 4.  Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets.

Authors:  Richard L Hauger; Victoria Risbrough; Olaf Brauns; Frank M Dautzenberg
Journal:  CNS Neurol Disord Drug Targets       Date:  2006-08       Impact factor: 4.388

5.  Brain stem catecholamines circuitry: activation by alcohol and role in the hypothalamic-pituitary-adrenal response to this drug.

Authors:  S Lee; Z Craddock; C Rivier
Journal:  J Neuroendocrinol       Date:  2011-06       Impact factor: 3.627

6.  Neuropeptide Y acts within the rat testis to inhibit testosterone secretion.

Authors:  Camryn D Allen; Beatrice Waser; Meike Körner; Jean Claude Reubi; Soon Lee; Catherine Rivier
Journal:  Neuropeptides       Date:  2010-11-26       Impact factor: 3.286

7.  NMR structure of the first extracellular domain of corticotropin-releasing factor receptor 1 (ECD1-CRF-R1) complexed with a high affinity agonist.

Authors:  Christy Rani R Grace; Marilyn H Perrin; Jozsef Gulyas; Jean E Rivier; Wylie W Vale; Roland Riek
Journal:  J Biol Chem       Date:  2010-09-15       Impact factor: 5.157

8.  Genetically encoded chemical probes in cells reveal the binding path of urocortin-I to CRF class B GPCR.

Authors:  Irene Coin; Vsevolod Katritch; Tingting Sun; Zheng Xiang; Fai Yiu Siu; Michael Beyermann; Raymond C Stevens; Lei Wang
Journal:  Cell       Date:  2013-11-27       Impact factor: 41.582

9.  Novel role of adrenergic neurons in the brain stem in mediating the hypothalamic-pituitary axis hyperactivity caused by prenatal alcohol exposure.

Authors:  I Y Choi; S Lee; C Rivier
Journal:  Neuroscience       Date:  2008-06-06       Impact factor: 3.590

Review 10.  Corticotropin-releasing factor peptide antagonists: design, characterization and potential clinical relevance.

Authors:  Jean E Rivier; Catherine L Rivier
Journal:  Front Neuroendocrinol       Date:  2013-11-20       Impact factor: 8.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.